Living Up to Expectations, A Double Victory at First Launch | Warm Congratulations to Chiheal Pharma Factory on the Successful Selection of Ornidazole Injection and Tranexamic Acid Injection in the Eighth Batch of National Drug Centralized Procurement!

Reading frequency:934  Updated on:2023-07-16

       

Chiheal Pharma Factory two products, ornidazole injection (specifications: 3ml:0.5g, 6ml:1.0g) and tranexamic acid injection (specification: 2.5ml:0.25g), have successfully entered the eighth batch of the national centralized procurement bidding list, exceeding expectations with a strong debut. Both products have been selected, a result that reflects the meticulous preparation and strategic leadership of the group's management, culminating in this outstanding achievement!

Ornidazole injection is a third-generation nitroimidazole drug. Once it enters susceptible cells, under anaerobic or low-oxygen conditions, the nitro group in its molecular structure is reduced to an amine group, producing active metabolites that interact with DNA. This inhibits the synthesis of nucleic acids and proteins, ultimately leading to the death of pathogenic microorganisms. It is currently one of the main products in the market for this class of drugs. According to data from Minea Network, in 2021, the sales of ornidazole injection in China’s public hospitals, county-level public hospitals, urban community centers, and township health centers (collectively referred to as Chinese public medical institutions) exceeded 1.8 billion yuan.

Tranexamic acid injection is primarily used to treat bleeding caused by systemic fibrinolysis hyperactivity, such as in conditions like leukemia, aplastic anemia, purpura, and abnormal bleeding during and after surgery. It is also used to treat local fibrinolysis hyperactivity-induced bleeding, such as pulmonary hemorrhage, nasal bleeding, genital bleeding, renal bleeding, and abnormal bleeding during and after prostate surgery. According to Yao Rongyun data, the national hospital sales of tranexamic acid injection in 2021 amounted to approximately 818 million yuan.

PREV: 没有了
NEXT: Good News: The Group\'s Second-Generation Innovative Drug, Marbaloxavir LHZH, Achieves Breakthrough Progress in Preclinical Research